AI chip heavyweights such as Samsung and TSMC are reporting record sales as demand for computing power surges, and that same engine is starting to reshape how Australian healthcare is delivered. Hospitals, clinics, and biotech groups are racing to plug AI into diagnosis, treatment, and drug discovery. This article walks through three Australian AI healthcare stocks from our screener that show how this shift is playing out in practice.
The three stocks covered below are just a starting sample from this theme. The full screen surfaced 5 more Australian AI healthcare companies with equally compelling narratives that are not unpacked in this article.
To size up the wider field and identify which AI healthcare plays best match your risk profile and time horizon, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener.
ImExHS (ASX:IME)
ImExHS is a small A$16 million healthcare technology stock that runs cloud-based imaging software and radiology services, feeding AI-ready datasets into diagnostics through its AQUILA, ALULA, and ANTEROS platforms, with about A$10 million from software and A$21 million from radiology.
ImExHS plugs directly into the AI healthcare theme because its imaging platforms and teleradiology workflows generate the structured data that machine learning models need, and management is already treating that pipeline as the engine for the next phase of the business.
"They also understand the challenge now is to drive the software sales and revenue much faster in 2026."
What happens to margins if a single unseen pressure on that AI-centred data pipeline tightens just as growth expectations peak?
If that pressure point is what matters most to you, the full narrative for ImExHS shows how ImExHS could accelerate or stall as AI workflows scale.
Paragon Care (ASX:PGC)
Paragon Care is a diversified medical distributor supplying everything from devices and consumables to digital ordering platforms, while also plugging AI-driven imaging systems into hospital workflows. It reports about A$3.5b from ANZ operations and A$160 million from Asia on a market value near A$240 million.
Paragon Care matters for this AI healthcare screen because it supplies the imaging hardware and AI-linked software that sit inside everyday hospital workflows, so the payoff hinges less on blue-sky tech promises and more on whether it can make those tools pay their way.
"The integration of recent acquisitions and ongoing operational synergies (with a target of $12 million annual run-rate in FY '26), coupled with the consolidation of business functions onto a unified JDE platform, are likely to improve cost efficiencies and structurally enhance net margins and EBITDA."
The real swing factor is what happens if a single assumption around funding costs and cash generation shifts just as AI imaging ramps up.
If that shift is what you are weighing, the full narrative for Paragon Care explains how Paragon Care could turn AI imaging, debt and margins into an accelerating story.
Artrya (ASX:AYA)
Artrya is a medical technology stock focused on Salix, an AI platform that reads coronary CT angiography scans to flag heart attack risk, with A$0.03 million from AI-driven CCTA analysis in Australia and a market value near A$539 million.
Artrya is closely aligned with the AI healthcare theme because Salix aims to move coronary disease diagnosis from manual visual review of scans to automated risk scoring, which can change how cardiology teams triage chest pain and allocate treatment.
"The SAPPHIRE multicenter real world study, targeting 10,000 to 12,000 scans across six high volume US systems and led by a well known principal investigator, is designed to build clinical evidence and brand credibility. This may support hospital adoption and help sustain longer term revenue and earnings growth if outcomes are favourable."
What happens to long term margins if one crucial assumption about how quickly hospitals adopt AI-guided coronary workflows proves too optimistic?
If that timing risk sits at the back of your mind, the full narrative for Artrya connects the dots between trial data, adoption curves and where Artrya’s story could accelerate next.
Seeking Fresh Alternatives Before They Fly
Fresh ideas move first, and the biggest breakouts often run before most investors even notice. Scan these new angles while they are still under the radar for now and look for opportunities early.
- Target stronger balance sheets by running the list of solid balance sheet and fundamentals (12 results) before momentum shifts and quality is fully reflected in broader market pricing.
- Consider structural demand for power infrastructure by reviewing the 43 power grid technology and infrastructure stocks while the grid upgrade story is developing, not only after prices have moved.
- Monitor the next wave of automation by scanning the 88 robotics and automation stocks before capital focuses on a narrow set of well known tickers.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com